A Rare Coexistence of Thyrotoxic Cardiomyopathy andAsthma in Graves’ Disease: Clinical Challenges andManagement Strategies: A Case Report
DOI:
https://doi.org/10.66266/inajemd.v2i2.64Keywords:
Graves’ disease, hyperthyroidism, asthma, thyrotoxic cardiomyopathyAbstract
Graves' disease is the most common autoimmune hyperthyroid disorder. Thyrotoxic cardiomyopathy (TCM) is a rare but potentially lethal complication of thyrotoxicosis, with an incidence of <1%. Betablocker is one of the drugs of choice in treating TCM. However, in asthma patient, beta-blocker may induce bronchoconstriction. We report a rare case of a 36-year-old male presented with complaints of shortness of breath, wheezing, cough, and palpitation. The patient had a history of asthma. Physical examination revealed diffuse thyroid enlargement, exophthalmos, tremor, cardiomegaly, irregular heart sounds, rales, wheezing in both lungs, and BMI was underweight. Wayne index was 20 (hyperthyroid) and Burch Wartofsky score was 35 (impending storm). Laboratory results showed low Thyroid-stimulating hormone level and high level of Free-T3, Free-T4, Thyroid-
Stimulating Hormone Receptor Antibodies, and N-terminal pro-B-type natriuretic peptide. Chest X-ray showed cardiomegaly. electrocardiogram showed atrial fibrillation RVR. Echocardiography
showed segmental wall motion abnormality EF 48%. Patient was diagnosed with Graves’ disease with hyperthyroidism, acute asthma exacerbation, Heart failure with mildly reduced ejection
fraction NYHA III due to thyrotoxic cardiomyopathy. Patient was treated with methimazole, shortacting beta-agonists, corticosteroid, digitalis, diuretics, anticoagulant, and angiotensin receptor blockers. During follow up, laboratory results, ECG, and clinical symptoms were improved. The management of Graves' disease with hyperthyroidism and TCM focuses primarily on controlling the thyroid hormone levels to prevent further cardiac deterioration. The complex interplay between managing thyroid hormone levels and preventing asthma exacerbation in this patient highlights the need for a multidisciplinary approach to optimize treatment outcomes. Graves' hyperthyroid patients with cardiomyopathy and asthma require holistic, comprehensive, and meticulous drug selection to prevent exacerbation.
Downloads
References
1. Pokhrel B, Bhusal K. Graves Disease.
Endocrinology. 2023 Jun 20;429–49.
2. Kanokwongnuwat W, Penpong N, Sangsri C.
Incidence and treatment outcomes of Graves’
disease in Thailand: a single-center retrospective
observational study. Thyroid Res. 2022 Dec
1;15(1):1–7.
3. PERKENI. Guidelines for the Management of
Hyperthyroid Disease. Indonesian Thyroidology
Study Group. 2017.
4. Meena MQ. Diagnosing Graves’ Disease and
Non-Graves Hyperthyroidism Using TSH
Receptor Antibody Test versus Non-TSH Receptor
Antibody Test Methods of Diagnosis. Open J
Endocr Metab Dis. 2020 Feb 17;10(2):7–17.
5. Arslan A, Altay H. Graves’ Disease and Cardiac
Complications. Graves’ Disease. 2021 May 26.
6. Modarresi M, Amro A, Amro M, Sobeih A, Okoro
U, Mansoor K, et al. Management of Cardiogenic
Shock due to Thyrotoxicosis: A Systematic
Literature Review. Curr Cardiol Rev. 2020 Mar
13;16(4):326–32.
7. Klein I, Danzi S. Thyroid Disease and the Heart.
Curr Probl Cardiol. 2016 Feb 1;41(2):65–92.
8. Ross DS, Burch HB, Cooper DS, Greenlee MC,
Laurberg P, Maia AL, et al. 2016 American
Thyroid Association Guidelines for Diagnosis
and Management of Hyperthyroidism and Other
Causes of Thyrotoxicosis. Thyroid. 2016 Oct
1;26(10):1343–421.
9. Quiroz-Aldave JE, del Carmen Durand-
Vásquez M, Lobato-Jeri CJ, Muñoz-Moreno
JM, Condori DCDG, Ildefonso-Najarro SP, et al.
Thyrotoxic Cardiomyopathy: State of the Art.
touchEndocrinology. 2023 May 25;19(1):78–84.
10. Huang KY, Tseng PT, Wu YC, Tu YK, Stubbs B, Su
KP, et al. Do beta-adrenergic blocking agents
increase asthma exacerbation? A network metaanalysis
of randomized controlled trials. Sci Rep.
2021 Dec 1;11(1).
11. Hashmi MF, Tariq M, Cataletto ME. Asthma.
StatPearls. 2024.
12. Toskala E, Kennedy DW. Asthma risk factors. Int
Forum Allergy Rhinol. 2015 Sep 1;5(Suppl 1):S11.
13. Lane LC, Wood CL, Cheetham T. Graves’ disease:
moving forwards. Arch Dis Child. 2022 Apr
1;108(4):276.
14. Grixti L, Lane LC, Pearce SH. The genetics of
Graves’ disease. Rev Endocr Metab Disord. 2024
Feb 1;25(1):203–14.
15. Qashqary M, Tobaiqy M, Al-Sutari MM, Mujallad
A, Alsheikh I. Prevalence of Suspected Cases
of Hyperthyroidism in Jeddah by Using
Wayne’s Scoring Index. Cureus. 2020 Nov
18;12(11):e11538.
16. Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022
Update on Clinical Management of Graves
Disease and Thyroid Eye Disease. Endocrinol
Metab Clin North Am. 2022 Jun 1;51(2):287–304.
17. Doubleday AR, Sippel RS. Hyperthyroidism.
Gland Surg. 2020 Feb 1;9(1):124.
18. Khalil Y, Dube MD, Woods L. Thyrotoxicosis-
Induced Cardiomyopathy With Systolic
Dysfunction. Cureus. 2023 Jan 20;15(1).
19. Bhattad PB, Roumia M. Cardio-Thyrotoxicosis
Syndrome: A Review of Thyrotoxic Cardiovascular
Disease. Cureus. 2023 Apr 17;15(4):e37659.
20. Raguthu CC, Gajjela H, Kela I, Kakarala CL, Hassan
M, Belavadi R, et al. Cardiovascular Involvement
in Thyrotoxicosis Resulting in Heart Failure: The
Risk Factors and Hemodynamic Implications.
Cureus. 2022 Jan 13;14(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).
